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Background: Hyaluronan is a large extracellular matrix molecule involved in several biological processes such as
proliferation, migration and invasion. In many cancers, hyaluronan synthesis is altered, which implicates disease
progression and metastatic potential. We have previously shown that synthesis of hyaluronan and expression of its
synthases 1–2 (HAS1-2) decrease in cutaneous melanoma, compared to benign melanocytic lesions.
Methods: In the present study, we compared immunohistological staining results of HAS1 and HAS2 with clinical
and histopathological parameters to investigate whether HAS1 or HAS2 has prognostic value in cutaneous
melanoma. The specimens consisted of 129 tissue samples including superficial (Breslow ≤ 1 mm) and deep
(Breslow > 4 mm) melanomas and lymph node metastases. The differences in immunostainings were analysed with
non-parametric Mann–Whitney U test. Associations between immunohistological staining results and clinical
parameters were determined with the χ2 test. Survival between patient groups was compared by the Kaplan-Meier
method using log rank test and Cox’s regression model was used for multivariate analyses.
Results: The expression of HAS1 and HAS2 was decreased in deep melanomas and metastases compared to
superficial melanomas. Decreased immunostaining of HAS2 in melanoma cells was significantly associated with
several known unfavourable histopathologic prognostic markers like increased mitotic count, absence of tumor
infiltrating lymphocytes and the nodular subtype. Furthermore, reduced HAS1 and HAS2 immunostaining in the
melanoma cells was associated with increased recurrence of melanoma (p = 0.041 and p = 0.006, respectively) and
shortened disease- specific survival (p = 0.013 and p = 0.001, respectively).
Conclusions: This study indicates that reduced expression of HAS1 and HAS2 is associated with melanoma
progression and suggests that HAS1 and HAS2 have a prognostic significance in cutaneous melanoma.
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Cutaneous melanoma is an aggressive type of skin can-
cer originating from pigment-producing melanocytic
skin cells. The incidence of cutaneous melanoma among
fair-skinned populations has risen significantly in recent
decades [1, 2]. The main risk factors for melanoma are* Correspondence: sanna.pasonen@uef.fi
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nevi [3, 4]. In the early stages of the disease, cutaneous
melanoma is curable with surgical excision. However, as
the disease progresses, melanoma cells acquire the ability
to metastasize. Cutaneous melanoma is highly metastatic,
and even in the early phases of the disease there is a small
subgroup of thin melanomas that develop metastases and
are not able to be cured surgically. Unfortunately, there
are no accurate prognostic or diagnostic biomarkers cur-
rently available to predict the progression of this disease.is distributed under the terms of the Creative Commons Attribution 4.0
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the extracellular matrix of most human tissues. It is
expressed abundantly in normal skin, in both the epider-
mis and dermis. Hyaluronan is formed on the plasma
membrane by three hyaluronan synthases (HAS 1–3)
and during its synthesis it is discharged into the extra-
cellular matrix. Hyaluronan, together with its primary
cell surface receptor CD44, have been shown to contrib-
ute to processes necessary for cancer development such
as migration, invasion and resistance to chemotherapeu-
tic drugs [5–9]. In addition, it has been reported that
hyaluronan and hyaluronan-fragments have angiogenic
properties in human endothelial cells and hyaluronan
contributes to wound healing and leukocyte adhesion via
long hyaluronan cables [10–12].
The role of hyaluronan in melanomagenesis has
remained obscure, partly due to previously published
conflicting results. Some in vitro studies suggest that
hyaluronan promotes melanoma cell migration and inva-
sion [13, 14], while in vivo studies indicate that reduced
expression of hyaluronan correlates positively with the
invasiveness of cutaneous melanoma [15, 16]. In mouse
models, elevated levels of circulating hyaluronan have
been shown to associate with decreased lung metastases
[17]. The expression of CD44 and hyaluronan is decreased
in human cutaneous melanomas and this is associated
with the progression of disease and poor prognosis [15].
Our previous work showed that hyaluronan content is
increased in the in situ melanomas compared to benign
nevi, whereas deep melanomas (Breslow > 4 mm) are
almost devoid of hyaluronan [16]. Similar decreased hya-
luronan content has been shown in squamous cell carcin-
omas (SCCs) of larynx, mouth and skin, which are tumors
originating from stratified epithelia [18–20]. Decreased tu-
moral hyaluronan content is accompanied by an increase
in the hyaluronan degrading enzyme, hyaluronidase 2
(HYAL2), and a decrease in HAS1 and HAS2 expression
in invasive melanomas and lymph node metastases com-
pared to benign nevi and in situ melanomas [16]. In con-
trast, hyaluronan content seems to be increased in tumors
originating from simple epithelia [7]. Thus, adenocarcin-
omas of the breast, colorectal and ovary have abundantly
hyaluronan in the tumor and stromal cells and this corre-
lates with an unfavorable prognosis [21–23].
Our previous work showed that decreased expression
of hyaluronan in the cutaneous melanoma is due to de-
creased expression of HAS1 and HAS2 and increased
expression of HYAL2. In the present study our aim was
to investigate whether HAS1-2 or HYAL2 have prognos-
tic value for cutaneous melanoma. Here we demonstrate
for the first time that decreased expression of HAS1 and
HAS2 favours melanoma progression and metastasis.
The immunostaining of both HAS1 and HAS2 was de-
creased in deeply invasive melanomas and lymph nodemetastases compared to superficial melanomas and this
associated with several known negative prognostic
factors. These tumors showed high HYAL2 immunostain-
ing levels but interestingly, it did not affect prognosis of
patients. Our work delivers new information about hyalur-
onan metabolism in cutaneous melanoma and identifies
HAS1 and HAS2 as possible prognostic factors in this
aggressive cancer.
Methods
Histological samples and clinical data
Paraffin embedded diagnostic tissue samples were taken
from invasive cutaneous melanomas (thickness < 1 mm
or > 4 mm, n = 82) and lymph node metastases (n = 47)
diagnosed between 1980–2010 in Kuopio University
Hospital. Invasive melanomas with Breslow depths less
than 1 mm or more than 4 mm were chosen to investigate
the difference between the groups representing relatively
different survival in general (in melanomas < 1 mm the
10-year survival is about 92 %, while in melanomas >
4 mm it is only about 10 %). The histopathological param-
eters were re-evaluated by an experienced histopathologist
(R.S), and the clinical patient data was collected. The
research has been approved by Committee on Research
Ethichs of the North Savo Hospital District and The
Finnish National Supervisory Authority for Welfare and
Health (VALVIRA). The registry study protocol was retro-
spective and thus the consent of the patients for participa-
tion was not required.
HAS1 and 2 and HYAL2 immunohistological stainings
After deparaffinization, the tissue sections were cooked
in 10 mM citrate buffer (pH 6.0) in a pressure cooker
for 15 minutes and after cooling washed with 0.1 M
phosphate buffer (PB; pH 7.0). The endogenous peroxid-
ase activity was blocked with 1 % H2O2 for 5 minutes.
Thereafter the sections were washed and incubated with
1 % bovine serum albumin (BSA), 0.05 % Tween-20 and
0.1 % Gelatin (Sigma G-2500) in PB for 30 minutes at
37 °C to block unspecific binding. After blocking, the
sections were incubated with goat polyclonal antibodies
for hyaluronan synthases diluted in 1 % BSA (HAS1
antibody 1:100 dilution and HAS2 antibody 1:120 dilu-
tion, Santa Cruz Biotechnology, Santa Cruz, CA).
HYAL2 2 was stained with rabbit polyclonal antibody,
(1:100 Abcam, Cambridge, UK). In controls, the primary
antibody was omitted. The specificity of the HAS and
HYAL2 antibodies was tested as described in our previ-
ous work [16]. The sections were incubated at 4 °C over-
night with primary antibodies. The following day, the
sections were rinsed with PB and incubated with bio-
tinylated secondary antibodies, anti-goat antibody
(1:1000, Vector Laboratories) diluted with 1 % BSA in
PB for HASes and anti-rabbit antibody (1:200, Vector
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visualized with avidin-biotin-peroxidase method (1:200,
Vector Laboratories, Irvine, CA) using 0.05 % 3,3-diami-
nobenzidine (DAB, Sigma, St.Louis, MO) as a substrate.
The Mayer’s hematoxylin counterstained sections were
mounted in DePex (BDH Laboratory Supplies, Poole,
England).
Evaluation of immunohistological stainings
The evaluation of the immunostainings was done inde-
pendently by two researchers (M.P., H.S.). The immuno-
staining coverages and the intensities were evaluated in
melanoma and stromal cells as previously described [16].
The amounts of immunopositive cells were estimated
with a five-level scoring system as follows; 1 = 0-5 %,
2 = 6-25 %, 3 = 26-50 %, 4 = 51-75 %, 5 = 76-100 %
(Additional file 1: Figure S1). The intensities of the
immunostainings were estimated with a four-level
scoring system from 0 to 3 as follows; negative (0),
weak (1), moderate (2) or strong (3).
Statistical analyses
Statistical analyses were performed with SPSS Statistics
21 (IBM). The differences in immunostainings between
all stages (pT1, pT4 and pN1-) were analysed with non-
parametric Mann–Whitney U test. Associations between
immunostainings and clinical data were determined with
χ2 test. For the χ2 test continuous variables wereTable 1 Clinical information of the patients (n =129)
Variable pT1 pT4
Number of cases 41 (31.8 %) 41
Gender
Male 22 (17.1 %) 24
Female 19 (14.7 %) 17
Age
under 20 0 (0.0 %) 1 (
20-59 18 (14.0 %) 14
60 and over 23 (17.8 %) 26
Any relapse
Yes 3 (2.4 %) 23
No 37 (29.1 %) 16
Spread at diagnosis 0 (0.0 %) 1 (
Alive
Yes 31 (24.0 %) 8 (
No 10 (7.8 %) 33
Cause of death
Melanoma 1 (1.2 %) 20
Other 5 (6.2 %) 7 (
Not known 4 (4.9 %) 6 (transformed into categorical variables. Univariate sur-
vival analyses of different groups were determined with
Kaplan-Meier log rank test. Two Kaplan-Meier log rank
test were performed to verify the accuracy of clinical
data (Additional file 2: Figure S2). Multivariate analyses
were performed with the Cox regression model. The
multivariate analyses tests were conducted separately for
two different groups because some histopathological
covariates were only analysed from primary cutaneous
melanoma samples (pT1 and pT4). Tests were con-
ducted only for primary cutaneous melanomas (pT1 and
pT4) without lymph node metastasis and for all stages
(pT1, pT4 and pN1-). The immunostaining categories 0
(0-5 %) and 1 (6- 26 %) were merged in the χ2 test,
Kaplan-Meier log rank test and Cox regression model
because of small group sizes. P-values less than 0.05
were considered statistically significant.
Results
Clinical information and histological samples were ob-
tained from 129 patients; 74 males (57.4 %) and 55
(42.6 %) females (Table 1). The samples consisted of 41
superficial melanomas (Breslow ≤ 1 mm, pT1), 41 deep
melanomas (Breslow > 4 mm, pT4) and 47 lymph node
metastases of melanoma (pN1). The most common cu-
taneous localization of primary melanoma was the back
(26.4 %). The mean age at the time of diagnosis was 59
(ranging between 5 – 92 years) and the mean follow-uppN1- Total
(31.8 %) 47 (36.4 %) 129 (100.0 %)
(18.6 %) 28 (21.7 %) 74 (57.4 %)
(13.2 %) 19 (14.7 %) 55 (42.6 %)
0.8 %) 1 (0.8 %) 2 (1.6 %)
(10.9 %) 26 (20.2 %) 58 (45.0 %)
(20.2 %) 20 (15.5 %) 69 (53.5 %)
(18.1 %) 39 (30.7 %) 65 (51.2 %)
(12.6 %) 3 (2.4 %) 56 (44.1 %)
0.8 %) 5 (3.9 %) 6 (4.7 %)
6.2 %) 9 (7.0 %) 48 (37.2 %)
(25.6 %) 38 (29.5 %) 81 (62.8 %)
(24.7 %) 32 (39.2 %) 53 (65.4 %)
8.6 %) 0 (0.0 %) 12 (14.8 %)
7.4 %) 6 (7.4 %) 16 (19.8 %)
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71 (55.0 %) patients had relapse or widely metastatic
disease at the time of diagnosis (Table 1). Interferon
treatment, chemotherapy and radiation therapy was
given to 32 (24.8 %), 36 (27.9 %) and to 41 (31.8 %) patients,
respectively, with metastatic disease (data not shown).
Decreased expression of HAS 1 and HAS 2 is associated
with the more advanced stages of melanoma
In superficial melanoma, melanoma cells were diffusely
immunostained with both HASes (Fig. 1a, d). In melan-
oma cells, both the cytoplasm and plasma membrane
showed immunoreactivity (up to 90 %), whereas most
(up to 80 %) of the stromal cells showed no immunopo-
sitivity (Additional file 3: Figure S3). When expressed,
HAS1 and HAS2 were localized in the cytoplasm and on
the plasma membrane of stromal cells (Fig. 1d, insert).
A decrease in HAS1 positive melanoma cells was asso-
ciated with advanced stage melanoma (p = 0.006; Table 2
and Fig. 2). Thus, the proportion of HAS1 immunoposi-
tive melanoma cells was significantly lower in LNFig. 1 HAS1 and HAS2 immunoreactivity in superficially and deeply invasiv
HAS1 a-c and HAS2 d-f in superficially a and d and deeply invasive melano
in a and d mark the border between the tumor and the stroma. Black
superficial melanoma. Black arrows a, d indicate melanin containing tumor ce
HAS2 immunopositive stromal cells. In deep melanoma and lymph node met
c, e, f. Scale bars 100 μmmetastases than in superficial (pT1) melanomas (p =
0.002; Fig. 2). Similarly, the proportion of HAS2 immu-
nopositive melanoma cells was significantly lower in
deeply invasive (pT4) melanomas and LN metastases
(pN1) (p = 0.013 and p = 0.012, respectively) compared
to superficial melanomas (Fig. 2). In addition, staining
intensity of HAS1 in melanoma cells was decreased
in LN metastases compared to deeply invasive melanomas
(p = 0.018, Fig. 2) and HAS2 intensity in melanoma cells
was decreased in deeply invasive melanomas compared to
superficial ones (p = 0.002; Fig. 2). Decreased HAS2 inten-
sity in melanoma cells was also associated with advanced
stage (p = 0.047; Table 2).
The overall proportion of immunopositive stromal
cells was 0-5 % (Additional file 3: Figure S3). Similar to
melanoma cells, the strongest HAS1 and HAS2 immu-
nostaining intensity in stromal cells was observed in
superficial melanomas (Fig. 1). Decreased immunostain-
ing intensity was observed in LN metastases compared
with superficial melanomas (p = 0.013 for HAS1, p <
0.001 for HAS2, Additional file 3: Figure S3).e melanomas and in lymph node metastases. Immunostainings of
mas b and e and in lymph node metastases c and f. Black dash lines
asterisk in a points to numerous tumor infiltrating lymphocytes in
lls in superficial melanoma and black arrowheads in (D, insert) point to
astasis tumor cells show weak immunostaining or are totally negative b,
Table 2 Correlation of HAS1 and HAS2 with clinical and histopathological factors
Variable HAS1 Coverage HAS1 Intensity HAS2 Coverage HAS2 Intensity
Stage p = 0.006 ns ns p = 0.047
pT1, pT4 or pN1-
Melanoma related death p = 0.007 ns p = 0.001 p = 0.016
Recurrence p = 0.021 ns p = 0.007 ns
Regional recurrence p = 0.006 p = 0.023 p = 0.007 ns
Distant recurrence p = 0.012 ns p = 0.001 p = 0.004
Genre ns ns ns ns
Age ns ns ns ns
Ulceration ns ns ns ns
TIL (low / moderate / high) ns ns p = 0.036 p = 0.040
Mitotic count (mitosis/mm2) ns ns ns p = 0.018
Horizontal diameter of melanoma (mm) ns ns p = 0.002 p =0.042
Growth type
Nodular ns ns ns p = 0.001
Stage = pT1, pT4 or pN1-. TIL = tumor-infiltrating lymphocytes (evaluated either low, moderate or high amount). Mitosis = mitosis/mm2, horizontal tumor
diameter (mm)
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melanoma related death
Decreased coverage of HAS2 immunostaining in melan-
oma cells was associated with several histopathological
factors, including reduced number of tumor infiltrating
lymphocytes (TILs) (p = 0.036) and increased horizontal
tumor diameter (p = 0.002; Table 2). Results were similar
for the intensity of HAS2 immunostaining; lower HAS2
intensity was associated with a reduced number of TILs
(p = 0.040), a larger horizontal diameter (p = 0.042),
nodular subtype (p = 0.001) and an increased mitotic ac-
tivity (p = 0.018; Table 2). On the other hand, increased
intensity of HAS2 in melanoma cells was associated with
superficial type (p = 0.047; data not shown). Neither
coverage nor intensity of HAS1 staining associated with
any histopathological factors (Table 2). Reduced HAS2
immunostaining (coverage and intensity) was associated
with melanoma-related death (p = 0.001 and p = 0.016,
respectively; Table 2). Furthermore, decreased HAS1
coverage in melanoma cells (p = 0.007; Table 2), and de-
creased intensity of HAS2 in the stromal cells, was posi-
tively associated with melanoma-related death (p = 0.038;
data not shown). Reduced coverage of HAS1 and HAS2
in melanoma cells was associated with recurrence of the
disease, both regional and distant (p = 0.021 and p =
0.007, respectively; Table 2 recurrence). Increased re-
gional recurrence was related to reduced number of
HAS1 and HAS2 –positive melanoma cells (p = 0.006
and p = 0.007, respectively; Table 2 regional and distant
recurrence). Similarly, increased distant recurrence was
related to reduced HAS1 and HAS2 positive melanoma
cells (p = 0.012 and p = 0.001, respectively; Table 2). De-
creased intensity of HAS1 in melanoma cells was relatedto increased regional metastasis (p = 0.023; Table 2),
while decreased intensity of HAS2 was associated with
distant metastasis (p = 0.004; Table 2).
Reduced expression of HAS 1 and HAS 2 is associated
with decreased disease-specific survival
At the end of the follow-up time, 48 patients were alive
and 81 had deceased. In melanoma cells, a reduced
amount of HAS1 positivity was associated with decreased
disease-specific survival (DSS) (p = 0.013; Fig. 3) and
recurrence-free survival (RFS) (p = 0.041, data not shown).
Similarly, decreased HAS2 coverage in melanoma cells
was associated with poorer DSS (p = 0.001; Fig. 3) and RFS
(p = 0.006; Fig. 3), and decreased intensity of HAS2 stain-
ing was related to shortened DSS (p = 0.014; Fig. 3). In
contrast, HAS1 intensity in melanoma cells was not associ-
ated with DSS. In stromal cells, HAS1 staining was not as-
sociated with either DSS or RFS, while decreased intensity
of HAS2 was associated with poorer DSS (p = 0.049, data
not shown) and RFS (p = 0.008, data not shown).
Multivariate analyses were done in two different ways;
for the primary cutaneous melanomas only (pT1 and
pT4) and for all stages (pT1, pT4 and pN1). Covariates
used in cutaneous melanomas (pT1 and pT4) were: Bre-
slow’s classification, ulceration, mitotic rate, patients age
and immunostaining results of HAS1 and HAS2. Signifi-
cant adverse prognostic factors for decreased DSS were
increased Breslow’s depth (p = 0.001) and decreased
HAS1 and HAS2 staining intensity in melanoma
cells (p = 0.019 and p = 0.011, respectively). For RFS,
significant adverse prognostic factors were deep invasion
(p < 0.001) and decreased HAS2 staining intensity of
melanoma cells (p = 0.014).
Fig. 2 Coverage and intensity of HAS1 and HAS2 immunostainings in melanoma cells of superficial melanoma (pT1), deep melanoma (pT4) and
lymph node metastasis (pN1-). Coverage and intensity of HAS1 immunostainings were successfully recorded from 112 samples. Coverage and
intensity of HAS2 immunostainings were recorded from 110 samples. Statistically significant differences between the stages are indicated with
brackets (Mann–Whitney U test). * p-value < 0.05, ** p-value <0.01, *** p-value <0.001
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(pT1, pT4 and pN1) were: patients’ age, stage (pT1, pT4
and pN1) and immunostaining results of HAS1 and
HAS2. Decreased coverage of HAS2 positive melanoma
cells was a significant negative prognostic factor (p =
0.039) for DSS, similar to increased stage (p = 0.001) and
age (p = 0.035). HAS1 immunostaining did not have
prognostic value for DSS.
Expression of Hyaluronidase 2 in melanoma
HYAL2 immunostaining localized mostly on the cyto-
plasm of the melanoma cells (Fig. 4). The proportion
of HYAL2 positive melanoma cells was mostly high
(76–100 %, data not shown) for all stages. Immunostain-
ing intensities of HYAL2 were statistically uniform in all
stages (Fig. 4). Between 50–60 % of samples had weak
intensity in all stages (data not shown).
Coverage of stromal immunostaining was between
0–50 % with no statistical differences between stages,
and there were no differences in the intensities ofstromal staining. In all stages, the staining intensities
of stromal cells were either weak or there were no
staining.
Discussion
The present work demonstrates that reduced expression
of HAS1 and HAS2 is associated with an unfavorable
prognosis in cutaneous melanoma. Reduced expression
of HAS1 and HAS2 is significantly associated with re-
duced DSS and RFS. In addition, weak immunostaining
of HAS2 in melanoma cells is associated with unfavorable
histopathologic prognostic markers such as increased mi-
totic count, absence of tumor infiltrating lymphocytes and
nodular subtype. Furthermore, multivariate analysis indi-
cates that decreased expression of HAS1 and HAS2 in
melanoma cells are independent prognostic factors.
Decreased tumoral hyaluronan content has been
shown to be an adverse prognostic factor in cutaneous
melanoma [15]. We have previously demonstrated that
decreased expression of HAS1 and HAS2 and increased
Fig. 3 Kaplan-Meier survival curves according to HAS1 and HAS2 expression. Kaplan-Meier log rank test indicating association of decreased HAS1
a and HAS2 b coverage and decreased intensity of HAS2 c in melanoma cells with declined disease-specific survival. Kaplan-Meier log rank test indicating
association of decreased HAS2 coverage with declined recurrence-free survival d. DSS = disease-specific survival, RFS = recurrence-free survival
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relates with decreased tumoral hyaluronan content in
the invasive melanomas [16]. In the present work, we
showed that decreased expression of HAS1 and HAS2
are adverse prognostic factors, while the expression ofFig. 4 HYAL2 immunostaining in superficially a and deeply invasive melan
numerous tumor infiltrating lymphocytes and black arrows immunopositiveHYAL2 does not affect the prognosis. Previously we
showed that HYAL2 expression is elevated in dysplastic
nevi and the expression is also elevated in locally invasive
and metastatic melanomas [16]. Whereas the expression
of HAS1 and HAS2 correlated with the content ofomas b and in lymph node metastases c. Black asterisk in a points to
tumor cells in superficial melanoma. Scale bar 100 μm
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altered until the invasive phase of the disease, at which
time hyaluronan content decreased [16]. This suggests
that HASes are responsible for intratumoral hyaluronan
concentration and they may have an adverse impact on
tumor progression by modulating hyaluronan content in
the tumor tissue.
Several melanoma cell lines synthesize substantial
amounts of hyaluronan in vitro [24, 25]. Furthermore,
melanoma cell-derived factors are able to induce hyalur-
onan synthesis in cutaneous fibroblasts via upregulation
of HAS2 [26]. These findings suggest that in melanoma
hyaluronan is produced by both melanoma and stromal
cells, but most likely the majority of intratumor hyaluro-
nan originates from melanoma cells. Our previous work
included in situ melanomas, which expressed excessively
hyaluronan [16]. Since in situ melanomas localize in
epidermis without any proper stromal component, it
is possible that the most of hyaluronan in these tu-
mors originates from melanoma cells and also from
epidermal keratinocytes, which are known to express
all HASes [27]. In addition to hyaluronan, several
other extracellular matrix molecules are also shown
to be involved in melanomagenesis like versican and
fibronectin [28–30]. Silencing of versican increases
cell proliferation and migration, whereas silencing of
fibronectin increases drug sensitivity of melanoma
cells [28, 30].
Hyaluronan metabolism in cutaneous melanoma seems
to differ from the main adenocarcinomas, such as the
breast carcinoma. Increased stromal hyaluronan content
has been associated with poor survival and tumor differ-
entiation in various human adenocarcinomas, whereas re-
duced levels of hyaluronan are associated with worsened
survival in melanoma and squamous cell carcinomas
(SCC) of the larynx, mouth and skin [15, 18–20]. Normal
skin, both epidermis and dermis, contains extensive
amounts of hyaluronan. Interestingly, the hyaluronan con-
centration is further increased in the in situ phase of mel-
anoma [16]. This increase in the early phase lesions has
also been observed in cutaneous, laryngeal and oral SCCs
[16, 18, 19, 31]. The results suggest that loss of hyaluronan
is associated with the acquisition of a motile, invasive
tumor cell phenotype. Increased content of hyaluronan
may reflect an attempt to maintain hyaluronan synthesis
at levels that are normal for the respective tissues. Physio-
logically, hyaluronan acts as a protective barrier against
harmful substances, microbes and UV radiation. Rauhala
showed that UVB exposure in keratinocytes causes in-
creased hyaluronan synthesis via up-regulation of HAS1-
3, which may have a protective effect on cells by increas-
ing viability and decreasing the secretion of inflammatory
mediators [27, 32]. Decrease of hyaluronan content in in-
vasive melanoma and SCCs may increase invasiveness ofthe tumor cells, which is in agreement with recent find-
ings where the accumulation of high molecular mass hya-
luronan exerted anticancer like effects in naked mole rats
[33]. This phenomenon was related to the exceptionally
large molecular size of hyaluronan in these animals. In-
deed, activation of hyaluronan degrading enzyme, HYAL2,
led to a reduction in the high molecular mass hyaluronan,
which resulted in tumor promotion in this model [33].
Moreover, our unpublished in vitro observations support
the idea that hyaluronan overexpression tends to restrict
melanoma cell growth, and melanoma cell lines (MV3
and C8161) overexpressing HAS3 show reduced cell mo-
tility and proliferation [25].
Knowledge of the prognostic significance of hyaluro-
nan synthases in malignant tumors is currently relatively
limited. In contrast to melanoma, increased HAS1-3 im-
munoreactivity is associated with poor survival in breast
cancer [34]. In particular, HAS2 has been shown to sup-
press tissue metalloproteinase inhibitor 1 which increases
the invasiveness of breast cancer cells [35]. Furthermore,
increased transcription levels of HAS1 and HYAL1 are as-
sociated with metastasizing urothelial bladder carcinoma
[36]. The prognostic value of a reduced HAS1-2 expres-
sion likely comes from decreased synthesis of hyaluronan.
However, the finding that HAS1 and 2 are independent
prognostic factors in melanoma raises the possibility that
these enzymes by themselves affect tumor progression.
For example, our unpublished in vitro observations indi-
cate that cell adhesion is reduced in melanoma cells over-
expressing HAS3 and this ability are not reversed with
eradication of hyaluronan [25]. These results suggest hya-
luronan synthesizing enzymes may independently affect
cell function in the absence of any direct effects on hyalur-
onan synthesis.
Our results demonstrate that the proportion of HAS1
and HAS2 and hyaluronan positive melanoma cells is
significantly decreased in lymph node metastases, com-
pared with superficially invasive melanoma. These results
indicate that decreased expression of HAS1 and HAS2,
and thus reduced tumoral hyaluronan content, is a
favorable feature for metastatic melanoma cells. Similarly,
ovarian carcinoma cells synthesizing low amounts of hya-
luronan were most adherent to the intra-abdominal peri-
toneal surfaces, suggesting that a large pericellular
hyaluronan coat acts as a barrier for adhesion and inhibits
peritoneal dissemination [37]. In addition to HAS1 and
HAS2 expression, the observed HYAL2 expression may
contribute to melanoma progression. The presence of hy-
aluronidase and hyaluronan fragments produced by hyal-
uronidases has been shown to mediate tumor progression
by stimulating angiogenesis and tumor invasion [38, 39].
HYAL2 degrades hyaluronan to oligosaccharides, which
may induce cleavage of the main cell surface hyaluronan
receptor, CD44, resulting in increased motility and
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cleave CD44, which may disturb the hyaluronan-CD44
interaction and release locally growing melanoma cells en-
abling the cells to spread [41]. In addition to CD44 shed-
ding, the expression of certain CD44 variants has been
shown to induce disease dissemination [42, 43]. Indeed,
the expression of receptor variant CD44v6 associates
strongly with brain metastases [42].
Our results indicate that reduced immunopositivity of
HAS2 is associated with several known unfavorable his-
topathologic prognostic markers like a reduced number
of tumor infiltrating lymphocytes (TIL), an increased
melanoma horizontal diameter, an increased mitotic activ-
ity and the nodular subtype. The proinflammatory effect
of hyaluronan has been previously comprehensively dem-
onstrated [10, 44, 45]. The presence of hyaluronan deposi-
tions, and the formation of hyaluronan cables, recruits
leukocytes to the site of inflammation and leukocytes
binding to these cables occur mainly via CD44 [46, 47].
Interaction of hyaluronan-CD44 is important in numerous
inflammatory diseases, such as allergic dermatitis and
inflammatory liver disease [48–50]. In melanoma, hyalur-
onan may increase leukocyte infiltration, and therefore,
the loss of hyaluronan could contribute to a reduction in
TILs, thereby worsening the prognosis [51, 52]. This is an
interesting finding since the majority of new therapies
in metastatic melanoma operate through activation of
immune responses [53].Conclusions
Caught in its early stages, melanoma can be cured by
surgery. However, despite a recent surge in the develop-
ment of new targeted therapies, metastatic melanoma
remains a major challenge to treat. Our novel data pro-
vides novel information about hyaluronan metabolism in
cutaneous melanoma and points towards a significant
role for HAS1 and HAS2 in melanoma dissemination.
Our results about correlation between decreased immu-
nostaining of HAS1 and HAS2 and decreased survival of
patients support the previous works and bring us new
information about histopathological changes that happen
during melanoma progression. However, whether de-
creased expression of HAS1 and HAS2 is the cause or a
secondary consequence of cutaneous melanoma is a
question that awaits further investigation.Additional files
Additional file 1: Figure S1. Evaluation of immunopositivity using five-
level scoring system. a and b representing 0-5 % of melanoma cells stained
positively, c representing 6-25 % of melanoma cells stained positively, d
representing 26-50 % of melanoma cells stained positively, e representing
51-75 % melanoma cells stained positively and f representing 76-100 % of
melanoma cells stained positively. Scale bar 100 μm. (TIF 19623 kb)Additional file 2: Figure S2. Clinical data’s accuracy was verified with
two Kaplan-Meier log rank tests. Kaplan-Meier log rank test according
stage (pT1, pT4 and pN1-) a. Patients with pT1 melanoma had better
prognosis than patients with pT4 melanoma or lymph node metastasis
(p <0.001). Kaplan-Meier log rank test according tumor-infiltrating
lymphocytes –status b. Tumor infiltrating lymphocytes status of pT1
and pT4 melanomas were analyzed and higher amounts of tumor-
infiltrating lymphocytes associated with better prognosis (p = 0.006).
DSS = disease-specific survival. (TIF 536 kb)
Additional file 3: Figure S3. Immunostaining results of HAS1 and HAS2
in stromal cells. Coverage and intensity of HAS1 and HAS2 immunostainings
in the stroma of superficial melanoma (pT1), deep melanoma (pT4) and
lymph node metastasis (pN1-). Coverage and intensity of HAS1
immunostainings were recorded from 95 and 96 samples, respectively.
Coverage and intensity of HAS2 immunostainings were recorded from 90
samples. Statistically significant differences between the stages are indicated
with brackets (Mann–Whitney U test). * p-value < 0.05, ** p-value <0.01,
*** p-value <0.001. (TIF 1091 kb)
Abbreviations
HA: Hyaluronan; HAS: Hyaluronan synthase; HYAL: Hyaluronidase;
DSS: Disease specific survival; RFS: Recurrence free survival; LN: Lymph node;
PB: Phosphate buffer; BSA: Bovine serum albumin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
MP analyzed histopathological specimens, participated on the collection of
the clinical data, performed the statistical analyses and drafted the
manuscript. AB participated on the collection of the clinical data and
commented on the manuscript. HS analyzed histopathological specimens
and commented on the manuscript. KTK organized clinical data collection
and commented on the manuscript. PA advised and helped performing the
statistical analyses and commented on the manuscript. SPS designed this
study and the immunohistological stainings, coordinated the study and
helped to draft the manuscript. RS designed this study, analyzed
histopathological specimens and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
The authors greatly acknowledge Mrs. Eija Rahunen and Mr. Kari Kotikumpu
for excellent technical assistance. Financial support for this work was
provided by The Academy of Finland, the Special Government Funding of
Kuopio University Hospital, The Spearhead Funds of the University of Eastern
Finland/Cancer Center of Eastern Finland and the Finnish Medical Society
Duodecim.
Author details
1Institute of Biomedicine, University of Eastern Finland, P.O. Box 1627 70211
Kuopio, Finland. 2Cancer Center, Kuopio University Hospital, Kuopio, Finland.
3Department of Dermatology, University of Eastern Finland and Kuopio
University Hospital, Kuopio, Finland. 4Institute of Clinical Medicine/Clinical
Pathology, University of Eastern Finland, Kuopio, Finland. 5Department of
Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. 6Cancer
Center of Eastern Finland, Kuopio, Finland.
Received: 8 July 2015 Accepted: 8 May 2016
References
1. Geller AC, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL,
Shaikh W, Miller DR. Melanoma epidemic: an analysis of six decades of data
from the Connecticut Tumor Registry. J Clin Oncol. 2013;31(33):4172–8.
2. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins CL,
Wingo PA. Recent trends in cutaneous melanoma incidence and death
rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5
Suppl 1):S17–25.e1-3.
Poukka et al. BMC Cancer  (2016) 16:313 Page 10 of 113. Lin WM, Luo S, Muzikansky A, Lobo AZ, Tanabe KK, Sober AJ, Cosimi AB,
Tsao H, Duncan LM. Outcome of patients with de novo versus nevus-associated
melanoma. J Am Acad Dermatol. 2015;72(1):54–8.
4. Moan J, Grigalavicius M, Baturaite Z, Dahlback A, Juzeniene A. The
relationship between UV exposure and incidence of skin cancer.
Photodermatol Photoimmunol Photomed. 2015;31(1):26–35.
5. Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, McCarthy JB,
Bullard KM. Hyaluronan facilitates invasion of colon carcinoma cells in vitro
via interaction with CD44. Cancer Res. 2004;64(13):4569–76.
6. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug
resistance in cancer cells by hyaluronan. J Biol Chem. 2003;278(28):25285–8.
7. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM.
Hyaluronan in human malignancies. Exp Cell Res. 2011;317(4):383–91.
8. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan
in human tumors: pathobiological and prognostic messages from cell-
associated and stromal hyaluronan. Semin Cancer Biol. 2008;18(4):288–95.
9. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44
and epidermal growth factor receptor in oncogenic signaling and
chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head
Neck Surg. 2006;132(7):771–8.
10. de la Motte CA, Hascall VC, Drazba J, Bandyopadhyay SK, Strong SA.
Mononuclear leukocytes bind to specific hyaluronan structures on colon
mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic
acid: inter-alpha-trypsin inhibitor is crucial to structure and function. Am J
Pathol. 2003;163(1):121–33.
11. Lokeshwar VB, Selzer MG. Differences in hyaluronic acid-mediated functions
and signaling in arterial, microvessel, and vein-derived human endothelial
cells. J Biol Chem. 2000;275(36):27641–9.
12. Tammi R, Pasonen-Seppanen S, Kolehmainen E, Tammi M. Hyaluronan
synthase induction and hyaluronan accumulation in mouse epidermis
following skin injury. J Invest Dermatol. 2005;124(5):898–905.
13. Edward M, Quinn JA, Pasonen-Seppanen SM, McCann BA, Tammi RH.
4-Methylumbelliferone inhibits tumour cell growth and the activation of
stromal hyaluronan synthesis by melanoma cell-derived factors. Br J
Dermatol. 2010;162(6):1224–32.
14. Ichikawa T, Itano N, Sawai T, Kimata K, Koganehira Y, Saida T, Taniguchi S.
Increased synthesis of hyaluronate enhances motility of human melanoma
cells. J Invest Dermatol. 1999;113(6):935–9.
15. Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ,
Alhava EM, Kosma VM. Reduced level of CD44 and hyaluronan associated
with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J
Pathol. 2000;157(3):957–65.
16. Siiskonen H, Poukka M, Tyynela-Korhonen K, Sironen R, Pasonen-Seppanen
S. Inverse expression of hyaluronidase 2 and hyaluronan synthases 1–3 is
associated with reduced hyaluronan content in malignant cutaneous
melanoma. BMC Cancer. 2013;13:181-2407-13-181.
17. Hirose Y, Saijou E, Sugano Y, Takeshita F, Nishimura S, Nonaka H, Chen YR,
Sekine K, Kido T, Nakamura T, Kato S, Kanke T, Nakamura K, Nagai R, Ochiya
T, Miyajima A. Inhibition of Stabilin-2 elevates circulating hyaluronic acid
levels and prevents tumor metastasis. Proc Natl Acad Sci U S A. 2012;
109(11):4263–8.
18. Hirvikoski P, Tammi R, Kumpulainen E, Virtaniemi J, Parkkinen JJ, Tammi M,
Johansson R, Agren U, Karhunen J, Kosma VM. Irregular expression of
hyaluronan and its CD44 receptor is associated with metastatic phenotype
in laryngeal squamous cell carcinoma. Virchows Arch. 1999;434(1):37–44.
19. Karvinen S, Kosma VM, Tammi MI, Tammi R. Hyaluronan, CD44 and versican
in epidermal keratinocyte tumours. Br J Dermatol. 2003;148(1):86–94.
20. Kosunen A, Ropponen K, Kellokoski J, Pukkila M, Virtaniemi J, Valtonen H,
et al. Reduced expression of hyaluronan is a strong indicator of poor
survival in oral squamous cell carcinoma. Oral Oncol. 2004;40(3):257–63.
21. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM.
High levels of stromal hyaluronan predict poor disease outcome in
epithelial ovarian cancer. Cancer Res. 2000;60(1):150–5.
22. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R,
Hirvikoski P, Eskelinen M, Kosma VM. Hyaluronan in peritumoral stroma and
malignant cells associates with breast cancer spreading and predicts
survival. Am J Pathol. 2000;156(2):529–36.
23. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P,
Agren U, Alhava E, Kosma VM. Tumor cell-associated hyaluronan as an
unfavorable prognostic factor in colorectal cancer. Cancer Res. 1998;
58(2):342–7.24. Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E,
Tammi RH, Tammi MI. 4-Methylumbelliferone inhibits hyaluronan synthesis
by depletion of cellular UDP-glucuronic acid and downregulation of
hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315(11):1914–23.
25. Takabe P, Bart G, Ropponen A, Rilla K, Tammi M, Tammi R, Pasonen-
Seppanen S. Hyaluronan synthase 3 (HAS3) overexpression downregulates
MV3 melanoma cell proliferation, migration and adhesion. Exp Cell Res.
2015;337(1):1–15.
26. Pasonen-Seppanen S, Takabe P, Edward M, Rauhala L, Rilla K, Tammi M,
Tammi R. Melanoma cell-derived factors stimulate hyaluronan synthesis in
dermal fibroblasts by upregulating HAS2 through PDGFR-PI3K-AKT and p38
signaling. Histochem Cell Biol. 2012;138(6):895–911.
27. Rauhala L, Hamalainen L, Salonen P, Bart G, Tammi M, Pasonen-Seppanen S,
et al. Low dose ultraviolet B irradiation increases hyaluronan synthesis in
epidermal keratinocytes via sequential induction of hyaluronan synthases
Has1-3 mediated by p38 and Ca2+/calmodulin-dependent protein kinase II
(CaMKII) signaling. J Biol Chem. 2013;288(25):17999–8012.
28. Hernandez D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Bassols A. Role
of versican V0/V1 and CD44 in the regulation of human melanoma cell
behavior. Int J Mol Med. 2011;27(2):269–75.
29. Bu P, Yang P. MicroRNA-203 inhibits malignant melanoma cell migration by
targeting versican. Exp Ther Med. 2014;8(1):309–15.
30. Afasizheva A, Devine A, Tillman H, Fung KL, Vieira WD, Blehm BH, et al.
Mitogen-activated protein kinase signaling causes malignant melanoma
cells to differentially alter extracellular matrix biosynthesis to promote cell
survival. BMC Cancer. 2016;16(1):186-016-2211-7.
31. Wang C, Tammi M, Guo H, Tammi R. Hyaluronan distribution in the normal
epithelium of esophagus, stomach, and colon and their cancers. Am J
Pathol. 1996;148(6):1861–9.
32. Hasova M, Crhak T, Safrankova B, Dvorakova J, Muthny T, Velebny V, Kubala
L. Hyaluronan minimizes effects of UV irradiation on human keratinocytes.
Arch Dermatol Res. 2011;303(4):277–84.
33. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al.
High-molecular-mass hyaluronan mediates the cancer resistance of the
naked mole rat. Nature. 2013;499(7458):346–9.
34. Auvinen P, Rilla K, Tumelius R, Tammi M, Sironen R, Soini Y, et al. Hyaluronan
synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer
grade and predict patient survival. Breast Cancer Res Treat. 2014;143(2):277–86.
35. Bernert B, Porsch H, Heldin P. Hyaluronan synthase 2 (HAS2) promotes
breast cancer cell invasion by suppression of tissue metalloproteinase
inhibitor 1 (TIMP-1). J Biol Chem. 2011;286(49):42349–59.
36. Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO, Acosta
K, et al. Association of hyaluronic acid family members (HAS1, HAS2, and
HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. 2011;117(6):
1197–209.
37. Tamada Y, Takeuchi H, Suzuki N, Aoki D, Irimura T. Cell surface expression of
hyaluronan on human ovarian cancer cells inversely correlates with their
adhesion to peritoneal mesothelial cells. Tumour Biol. 2012;33(4):1215–22.
38. Fieber C, Baumann P, Vallon R, Termeer C, Simon JC, Hofmann M, et al.
Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell
Sci. 2004;117(Pt 2):359–67.
39. Rodgers LS, Lalani S, Hardy KM, Xiang X, Broka D, Antin PB, Camenisch TD.
Depolymerized hyaluronan induces vascular endothelial growth factor, a
negative regulator of developmental epithelial-to-mesenchymal
transformation. Circ Res. 2006;99(6):583–9.
40. Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells
enhance their own CD44 cleavage and motility by generating hyaluronan
fragments. J Biol Chem. 2006;281(9):5861–8.
41. Duterme C, Mertens-Strijthagen J, Tammi M, Flamion B. Two novel functions
of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of
CD44-ERM interactions. J Biol Chem. 2009;284(48):33495–508.
42. Marzese DM, Liu M, Huynh JL, Hirose H, Donovan NC, Huynh KT, Kiyohara E,
Chong K, Cheng D, Tanaka R, Wang J, Morton DL, Barkhoudarian G, Kelly
DF, Hoon DS. Brain metastasis is predetermined in early stages of cutaneous
melanoma by CD44v6 expression through epigenetic regulation of the
spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.
43. Zhang P, Fu C, Bai H, Song E, Song Y. CD44 variant, but not standard CD44
isoforms, mediate disassembly of endothelial VE-cadherin junction on
metastatic melanoma cells. FEBS Lett. 2014;588(24):4573–82.
44. Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation.
Front Immunol. 2014;5:101.
Poukka et al. BMC Cancer  (2016) 16:313 Page 11 of 1145. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D,
Beutler B, Gallo RL. Recognition of hyaluronan released in sterile injury
involves a unique receptor complex dependent on Toll-like receptor 4,
CD44, and MD-2. J Biol Chem. 2007;282(25):18265–75.
46. de La Motte CA, Hascall VC, Calabro A, Yen-Lieberman B, Strong SA.
Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on
human intestinal mucosal smooth muscle cells after virus infection or
treatment with poly(I.C). J Biol Chem. 1999;274(43):30747–55.
47. Kessler S, Rho H, West G, Fiocchi C, Drazba J, de la Motte C. Hyaluronan
(HA) deposition precedes and promotes leukocyte recruitment in intestinal
inflammation. Clin Transl Sci. 2008;1(1):57–61.
48. Gonda A, Gal I, Szanto S, Sarraj B, Glant TT, Hunyadi J, Mikecz K. CD44, but
not l-selectin, is critically involved in leucocyte migration into the skin in a
murine model of allergic dermatitis. Exp Dermatol. 2005;14(9):700–8.
49. McDonald B, McAvoy EF, Lam F, Gill V, de la Motte C, Savani RC, et al.
Interaction of CD44 and hyaluronan is the dominant mechanism for
neutrophil sequestration in inflamed liver sinusoids. J Exp Med.
2008;205(4):915–27.
50. McDonald B, Kubes P. Interactions between CD44 and Hyaluronan in
Leukocyte Trafficking. Front Immunol. 2015;6:68.
51. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating
lymphocytes predict sentinel lymph node positivity in patients with
cutaneous melanoma. J Clin Oncol. 2007;25(7):869–75.
52. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H,
Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA,
Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H,
Begg CB, Berwick M. Tumor-infiltrating lymphocyte grade in primary
melanomas is independently associated with melanoma-specific survival in
the population-based genes, environment and melanoma study. J Clin
Oncol. 2013;31(33):4252–9.
53. Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system
to provide long-term survival in patients with melanoma and other solid
tumors. Oncoimmunology. 2014;3(1):e27560.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
